Merck to Acquire Acceleron for ~$11.5B

Shots:

Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing price. The transaction is expected to close in Q4’21
The acquisition will strengthen Merck’s cardiovascular pipeline. Acceleron’s sotatercept is currently in P-III trials & has the potential to improve short-term & long-term clinical outcomes in patients with PAH
In 2011, Acceleron has entered into a collaboration with BMS to develop and commercialize Reblozyl. The therapy has been approved in the US, EU, Canada, and Australia for the treatment of anemia in rare blood disorders

Click here to read full press release/ article | Ref: Merck | Image: Spagnola & Associates